Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
ConclusionIn vitro, daratumumab is not toxic to mobilized CD34+ progenitor cells from myeloma patients.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Hematology | Myeloma | Stem Cell Therapy | Stem Cells | Toxicology | Transplants